{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:29:50Z","timestamp":1767918590482,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14318-2","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T18:11:52Z","timestamp":1747937512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Jacques","family":"Raphael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Blanchette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"14318_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s43018-020-0074-y","volume":"1","author":"M -Richards","year":"2020","unstructured":"Richards M, Anderson M, Carter P, et al. The impact of the COVID-19 pandemic on cancer care. Nat Cancer. 2020;1:565\u20137. https:\/\/doi.org\/10.1038\/s43018-020-0074-y","journal-title":"Nat Cancer"},{"key":"14318_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/CCI.20.00134","volume":"4","author":"D -Patt","year":"2020","unstructured":"Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, Markward N, Sullivan M, Peng J, Zhou A. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inf. 2020;4:1059\u201371. https:\/\/doi.org\/10.1200\/CCI.20.00134. PMID: 33253013; PMCID: PMC7713534.","journal-title":"JCO Clin Cancer Inf"},{"issue":"10","key":"14318_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW -Lee","year":"2020","unstructured":"Lee LYW, Cazier JB, Starkey T, UK Coronavirus Cancer Monitoring Project Team, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309\u201316. Epub 2020 Aug 24. Erratum in: Lancet Oncol. 2020 Sep 3.","journal-title":"Lancet Oncol"},{"key":"14318_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","volume":"139","author":"KS -Saini","year":"2020","unstructured":"Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43\u201350. Epub 2020 Sep 2.","journal-title":"Eur J Cancer"},{"key":"14318_CR5","doi-asserted-by":"publisher","unstructured":"Kuderer NM, Choueiri TK, Shah DP et al. COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907\u20131918. https:\/\/doi.org\/10.1016\/S0140-6736(20)31187-9. Epub 2020 May 28. Erratum in: Lancet. 2020;396(10253):758.","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"14318_CR6","doi-asserted-by":"publisher","first-page":"103365","DOI":"10.1016\/j.critrevonc.2021.103365","volume":"163","author":"M -Tagliamento","year":"2021","unstructured":"Tagliamento M, Agostinetto E, Bruzzone M, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103365. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103365. Epub 2021 May 27.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"14318_CR7","doi-asserted-by":"publisher","first-page":"1824646","DOI":"10.1080\/2162402X.2020.1824646","volume":"9","author":"B -Wang","year":"2020","unstructured":"Wang B, Huang Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis. Oncoimmunology. 2020;9(1):1824646.","journal-title":"Oncoimmunology"},{"key":"14318_CR8","doi-asserted-by":"publisher","unstructured":"Lee LY, Cazier JB, Angelis V, Arnold R, UK Coronavirus Monitoring Project Team, Kerr R, Middleton G et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919\u20131926. https:\/\/doi.org\/10.1016\/S0140-6736(20)31173-9. Epub 2020 May 28. Erratum in: Lancet. 2020;396(10250):534.","DOI":"10.1016\/S0140-6736(20)31173-9"},{"key":"14318_CR9","doi-asserted-by":"publisher","unstructured":"Rogiers A, Pires da Silva I, Tentori C et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021;9(1):e001931. https:\/\/doi.org\/10.1136\/jitc-2020-001931. Erratum in: J Immunother Cancer. 2021;9(10):e001931corr1. doi: 10.1136\/jitc-2020-001931corr1. Erratum in: J Immunother Cancer. 2022;10(3):e001931corr2. https:\/\/doi.org\/10.1136\/jitc-2020-001931. PMID: 33468556; PMCID: PMC7817383.","DOI":"10.1136\/jitc-2020-001931"},{"issue":"10","key":"14318_CR10","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI -Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, RECORD Working Committee, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885. PMID: 26440803; PMCID: PMC4595218.","journal-title":"PLoS Med"},{"issue":"1","key":"14318_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3747\/co.v16i1.297","volume":"16","author":"T -Vandenberg","year":"2009","unstructured":"Vandenberg T, Coakley N, Nayler J, et al. A framework for the organization and delivery of systemic treatment. Curr Oncol. 2009;16(1):4\u201315. https:\/\/doi.org\/10.3747\/co.v16i1.297. PMID: 19229367; PMCID: PMC2644625.","journal-title":"Curr Oncol"},{"issue":"3","key":"14318_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jha2.167","volume":"2","author":"D -Tremblay","year":"2021","unstructured":"Tremblay D, Rapp JL, Alpert N, et al. Mild anemia as a single independent predictor of mortality in patients with COVID-19. EJHaem. 2021;2(3):319\u201326. https:\/\/doi.org\/10.1002\/jha2.167. PMID: 34226904; PMCID: PMC8242891.","journal-title":"EJHaem"},{"issue":"1","key":"14318_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13027-020-00339-y","volume":"15","author":"M -Sorouri","year":"2020","unstructured":"Sorouri M, Kasaeian A, Mojtabavi H, et al. Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study. Infect Agent Cancer. 2020;15(1):74. https:\/\/doi.org\/10.1186\/s13027-020-00339-y. PMID: 33334375; PMCID: PMC7745169.","journal-title":"Infect Agent Cancer"},{"issue":"4","key":"14318_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.adro.2020.04.028","volume":"5","author":"R -Kabarriti","year":"2020","unstructured":"Kabarriti R, Brodin NP, Maron MI, Tom\u00e9 WA, Halmos B, Guha C, Kalnicki S, Garg MK, Ohri N. Extent of prior lung irradiation and mortality in COVID-19 patients with a Cancer history. Adv Radiat Oncol. 2020;5(4):707\u201310. PMID: 32775778; PMCID: PMC7239013.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"14318_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","volume":"8","author":"M -Chavez-MacGregor","year":"2022","unstructured":"Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69\u201378. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5148. PMID: 34709356; PMCID: PMC8554684.","journal-title":"JAMA Oncol"},{"issue":"1","key":"14318_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.20892\/j.issn.2095-3941.2020.0559","volume":"18","author":"L -Yang","year":"2021","unstructured":"Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1):298\u2013307. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0559. PMID: 33628602; PMCID: PMC7877167.","journal-title":"Cancer Biol Med"},{"key":"14318_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P -Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"issue":"9","key":"14318_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2021.1887131","volume":"21","author":"PS -Pezeshki","year":"2021","unstructured":"Pezeshki PS, Rezaei N. Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opin Biol Ther. 2021;21(9):1173\u20139. https:\/\/doi.org\/10.1080\/14712598.2021.1887131. Epub 2021 Feb 17. PMID: 33543652; PMCID: PMC7898453.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"14318_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(24)00107-4","volume":"25","author":"L -Turtle","year":"2024","unstructured":"Turtle L, Elliot S, Drake TM, et al. Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study. Lancet Oncol. 2024;25(5):636\u201348. Epub 2024 Apr 12. PMID: 38621404.","journal-title":"Lancet Oncol"},{"key":"14318_CR20","doi-asserted-by":"publisher","unstructured":"V\u00e1rnai C, Palles C, Arnold R et al. UKCCMP Team. Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open. 2022;5(2):e220130. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0130. Erratum in: JAMA Netw Open. 2022;5(4):e2210276. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.10276. PMID: 35188551; PMCID: PMC8861846.","DOI":"10.1001\/jamanetworkopen.2022.0130"},{"issue":"23","key":"14318_CR21","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.3390\/cancers14235954","volume":"14","author":"H -Hatic","year":"2022","unstructured":"Hatic H, Hearld KR, Das D, Deshane J. Clinical outcomes in COVID-19 patients treated with immunotherapy. Cancers (Basel). 2022;14(23):5954. https:\/\/doi.org\/10.3390\/cancers14235954. PMID: 36497435; PMCID: PMC9735726.","journal-title":"Cancers (Basel)"},{"key":"14318_CR22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC -Garassino","year":"2020","unstructured":"Garassino MC, Whisenant JG, Huang L-C, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914\u201322.","journal-title":"Lancet Oncol"},{"key":"14318_CR23","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"LY -Lee","year":"2020","unstructured":"Lee LY, Cazier J-B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919\u201326.","journal-title":"Lancet"},{"key":"14318_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV -Robilotti","year":"2020","unstructured":"Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218\u201323.","journal-title":"Nat Med"},{"issue":"8","key":"14318_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/vaccines10081195","volume":"10","author":"MA -Lopez-Olivo","year":"2022","unstructured":"Lopez-Olivo MA, Valerio V, Karpes Matusevich AR, et al. Safety and efficacy of influenza vaccination in patients receiving immune checkpoint inhibitors. Systematic review with Meta-Analysis. Vaccines (Basel). 2022;10(8):1195. https:\/\/doi.org\/10.3390\/vaccines10081195. PMID: 36016085; PMCID: PMC9412390.","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"14318_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.vaccine.2024.01.023","volume":"42","author":"AA -Grima","year":"2024","unstructured":"Grima AA, Kwong JC, Richard L, et al. Canadian immunization research network (CIRN) investigators. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: a self-controlled case series study using administrative data. Vaccine. 2024;42(7):1498\u2013505. Epub 2024 Feb 9. PMID: 38341288.","journal-title":"Vaccine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14318-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T18:11:53Z","timestamp":1747937513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14318-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14318"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14318-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a prescribed entity under Ontario\u2019s privacy legislation [Personal Health Information Protection Act (PHIPA)], ICES is authorized to collect and use health care data for the purposes of health system analysis, evaluation, and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario. Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. As such, the use of the data in this project is authorized under section 45 and approved by ICES\u2019 Privacy and Legal Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. Raphael: advisory boards with Merck, Lilly, AstraZeneca and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"922"}}